Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: A case report and literature review

21Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Paclitaxel (PTX) and/or cisplatin (CDDP), as important cytotoxic anti-cancer agents, are widely used to treat various solid tumors. Both may cause moderate or severe neurotoxicity, but ocular neurotoxicity is also occasionally reported. A patient diagnosed with nasopharyngeal cancer suffering acute ocular neurotoxicity 10 days after paclitaxel and CDDP administration at the recommended dose is described in the present case report, and PTX- and/or CDDP-induced ocular neurotoxicity are summarized according to previous reports. Possible mechanisms and the potential diagnostic, therapeutic and predictive strategies of PTX- and/or CDDP-induced ocular neurotoxicity are reviewed, to help the oncologist to take the infrequent toxicity of cytotoxic drugs into account and improve patient safety during anti-cancer therapy. © 2014 Li et al.

Cite

CITATION STYLE

APA

Li, Y., Li, Y., Li, J., Pi, G., & Tan, W. (2014). Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: A case report and literature review. OncoTargets and Therapy, 7, 1361–1366. https://doi.org/10.2147/OTT.S65774

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free